A long survivor with local relapse of hilar cholangiocarcinoma after R1 surgery treated with chemoradiotherapy: a case report and literature review by unknown
CASE REPORT Open Access
A long survivor with local relapse of hilar
cholangiocarcinoma after R1 surgery
treated with chemoradiotherapy: a case
report and literature review
Hirohisa Okabe1,3, Akira Chikamoto1, Masataka Maruno1, Daisuke Hashimoto1, Katsunori Imai1, Katsunobu Taki1,
Kota Arima1, Takatoshi Ishiko1, Hideaki Uchiyama3, Toru Ikegami3, Norifumi Harimoto3, Shinji Itoh3,
Tomoharu Yoshizumi3, Toru Beppu2, Hideo Baba1* and Yoshihiko Maehara3
Abstract
The treatment outcome of extrahepatic cholangiocarcinoma remains insufficient because it is difficult to obtain
accurate diagnosis of tumor spreading and effective treatment agent is quite limited in spite of substantial current
efforts, all of which have been unsuccessful except for gemcitabine plus cisplatin. The patient was a 60-year-old
female who had developed hilar cholangiocarcinoma and underwent extrahepatic bile duct resection. Although
it was conceivable that it would be the R1 resection, the patient wanted to receive limited resection to avoid
postoperative complication mainly because she was depressed. In histology, interstitial spreading of tumor was
appreciated at the surgical margin of bile duct. The patient did not accept to receive the additional treatment
after the surgery and hardly visited the hospital to take the periodical test for monitoring the residual cancer
cells. As expected, the local relapse of tumor was appreciated 1 year after the R1 surgery. She chose radiotherapy
and agreed with subsequent S-1 treatment for 26 months. Consequently, elevated CA19-9 was decreased, and
local relapse has been successfully controlled for more than 7 years after the relapse of tumor. Here, we report
quite a rare case in terms of long survivor after chemoradiotherapy on locally relapsed unresectable hilar
cholangiocarcinoma.
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Background
Curative resection of extrahepatic cholangiocarcinoma
remains challenging mainly due to the limitation of diag-
nosis regarding vertical and horizontal tumor spreading.
Although prognosis of R1 surgery on extrahepatic
cholangiocarcinoma is reported to be better than that of
best supportive care, the optimal additional treatment
for R1 surgery is controversial and has not been
reviewed so far. Here, we aim to report a case who has
successfully survived for long time after R1 surgery on
hilar cholangiocarcinoma and review the treatment on
extrahepatic cholangiocarcinoma patients with R1
surgery.
Surgical resection or liver transplantation remains the
only curative treatment that can offer long-term survival
for hilar cholangiocarcinoma (Hl-CC) [1, 2]. Despite the
preoperative and surgical advances for Hl-CC, some pa-
tients still have microscopic positive resection (R1) and
recurrence occurs in many of them even after curative
resection (R0). For patients who unfortunately have
unresectable Hl-CC or the unresectable recurrence after
curative resection, gemcitabine plus cisplatin is the only
effective therapeutic agent that has been globally appre-
ciated based on the proper clinical study to date [3].
Here, we report the case representing the local relapse
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of Hl-CC after R1 surgery and long-term survival with
the treatment of radiation and subsequent chemotherapy
and discuss the previous outcome of concomitant treat-
ment plus surgery in extrahepatic cholangiocarcinoma
(ECC) patients with R1 surgery.
Case presentation
A 60-year-old female visited a local hospital due to jaun-
dice but did not have abdominal pain. She was then
referred to our department for the surgical treatment.
Total bilirubin level was 25.6 mg/dL, and enzymes, such
as AST, ALT, and gamma-GTP, are also high. Percutan-
eous transhepatic bile duct drainage (PTBD) was
performed, and cholangiography was done (Fig. 1a). In
contrast enhanced computed tomography (CT), there
was an enhanced lesion in hilar biliary tract and dilation
of intrahepatic duct was appreciated (Fig. 1b). With the
endoscopic retrograde cholangio-pancreatography (ERCP),
there was an obstruction of biliary tract and biopsy-
proved adenocarcinoma. Hence, she was diagnosed
with hilar bile tract carcinoma. There was no distant
metastasis. She was depressed, but the disease was
under control with the medication.
After the jaundice improved, we planned right hemi-
hepatectomy and extrahepatic bile duct resection. How-
ever, the patient rejected extensive surgery. The reason
was that she wanted to have postoperative complications
not to worsen her depressive condition. Finally, she
chose limited operation which was the resection of ex-
trahepatic bile duct (Fig. 2a). Gall stone was appreciated
and wall thickness was extended into the gall bladder
(Fig. 1b). Extension of the lesion (red line) is shown in
Fig. 3a. The lesion expanded into the gall bladder. The
tumor was well-differentiated adenocarcinoma with no
lymph node metastasis. Perineural invasion was positive,
and lymphovascular invasion was negative. Surgical
margins at both proximal (hepatic) and distal (pancre-
atic) side were positive. Carcinoma cells were appreci-
ated at both biliary epithelia (Fig. 3b) and submucosal
stroma (Fig. 3c).
A B
Fig. 1 Preoperative imaging of hilar cholangiocarcinoma. a Stenosis of proximal biliary tract is appreciated through percutaneous transhepatic
biliary drainage catheter. b Computed tomography shows the tumor with slight enhancement. Arrow represents the tumor
A B
Fig. 2 The specimen of hilar cholangiocarcinoma extending to cystic duct. a Extrahepatic bile duct was resected. b Circled 1 represents right hepatic duct;
circled 2 represents left hepatic duct; circled 3 represents cystic duct. Abnormal epithelia is widely seen in resected biliary tract including cystic duct
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We recommended her to receive chemotherapy, but
she declined to do it. In addition, she hardly came to the
hospital for the routine test. One year later, in contrast
enhanced CT, intrahepatic bile duct was dilated (Fig. 4a)
and abnormal thick soft tissue at anastomotic site
showed up (Fig. 4b). Tumor marker CA19-9 was
remarkably elevated (Fig. 5). Local relapse of residual
cancer cells was macroscopically appreciated as an inev-
itable consequence of R1 surgery. Since standard chemo-
therapy was not yet established at that time, she chose
the radiotherapy. The patient underwent CT simulation,
and clinical target volume was the gross total volume
which was the recurrent mass seen on CT plus 0.5–1.0-
cm margin. Three-dimensional comformal radiotherapy
was planned, and the clinical target volume was irradi-
ated with 50 Gy at a daily dose of 2.0 Gy. After 50 Gy of
radiation was completed, the dilation of biliary duct was
improved. In addition, we recommended her to subse-
quently receive chemotherapy with tegafur-gimeracil-
oteracil-potassium (S-1, 100 mg/body). Since she was
tolerable to keep taking the drug, S-1 treatment was
continued for 26 months. There has been neither re-
elevation of CA19-9 nor relapse of tumor for more than
7 years since S-1 treatment was stopped.
A B
C
Fig. 3 Pathological findings of hilar cholangiocarcinoma. a Extension of the hilar cholangiocarcinoma. Red line represents the existence of
cancer cells evaluated with several paraffin blocks (open yellow rectangles). Paraffin block numbers are shown as orange-colored circled
numbers. b Cholangiocarcinoma cells are seen in biliary epithelia at the surgical margin on hepatic side. c Cholangiocarcinoma cells are
also seen in submucosal area. ×400 magnification
BA
Fig. 4 Computed tomography of the relapse of cholangiocarcinoma. a, b Intrahepatic bile duct is dilated, and low-density tumor is appreciated
at the hilum of the liver. Arrows represent the low density tumor which is the relapse of residual cancer cells at surgical margin of biliary tract
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Discussion
The patient who has successfully controlled the local
relapse of Hl-CC after R1 surgery is introduced in the
current study. To the best of our knowledge, this is quite
a rare case because patients who have interstitial inva-
sion of cancer cells at the surgical margin show worse
prognosis than superficial spreading of cancer cell [4, 5],
suggesting that additional locoregional treatment strat-
egy might improve the elimination of microscopic
residual cancer cells (Fig. 6). A review of the literature
allowed the identification of several reports proposing
additional treatment on R1 patients (Table 1). Large
scale study in Korea showed that R1 surgery plus radio-
therapy or chemoradiotherapy improved the occurrence
of local recurrence rate and that both concomitant
chemotherapy and chemoradiotherapy improved the oc-
currence of distant metastasis [6]. Although the benefit
of concomitant chemotherapy needs further investiga-
tion, local relapse rate shown in several studies might
decrease by additional radiotherapy with or without
chemotherapy; 12–39 % versus surgery alone or surgery
plus chemotherapy; 58–59 % [6–9]. However, local re-
lapse also depends on the biological characteristics and
interstitial spreading of cancer cell [4]. Population-based
analysis from the University of Texas suggested that ad-
juvant radiotherapy improved early survival compared
with surgery alone in a multifactorial model, although
adjuvant RT may be associated with long-term (>5 years)
survival decrement in univariate analysis [10].
To date, only gemcitabine plus cisplatin has been
accepted for first-line therapy for unresectable biliary
tract cancer [3], and the subsequent challenges fail to
establish the next promising therapeutic agent [11, 12].
S1 treatment might be effective for some patients if we
can select the good responder to S1 treatment or ar-
range the optimal dose of drug [13]. In this case, S1
treatment plus radiotherapy was eventually effective.
However, it was difficult to determine when adjuvant S1


















Fig. 5 Change of CA19-9 level. CA19-9 level decreased after surgery and re-elevated at the tumor relapse. After the radiation and subsequent
chemotherapy, the level was decreased and controlled for more than 6 years
Fig. 6 Computed tomography of the treated liver 6 years after the
tumor relapse. Neither dilatation of intrahepatic bile duct nor tumor
relapse is seen in the latest CT imaging
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S1 treatment, and we continued it for more than 2 years.
Translational research is required for finding the bio-
marker selecting those patients responsive to 5-FU based
treatment or the new strategy of how to use 5-FU based
chemotherapeutic agent and how long to continue the
treatment. Since the efficacy of radiotherapy alone is
limited in terms of the locoregional therapy, the combin-
ation of chemotherapy and radiotherapy seems to be
best additional option to control residual cancer cells at
the locoregional area as well as latent cells in distant
organ. Furthermore, postoperative complications post-
pone the chance of adjuvant chemotherapy resulting in
the propagation of residual cancer cells. In this sense,
neoadjuvant supportive treatment might be the best way
to control microscopic cancer cells both around the
main tumor and in distant organ, which are hard to
eradicate by surgery alone. Neoadjuvant chemoradiation
plus liver transplantation provided promising outcome
for patients with perihilar cholangiocarcinoma [14].
Conclusions
R0 resection is the most effective treatment for hilar
cholangiocarcinoma. However, we encounter the pa-
tients who resulted in receiving R1 surgery in spite of
extended surgical procedure due to the limitation of
accuracy in diagnosis. Concomitant treatment for
ECC patients with R1 surgery has not been estab-
lished. Local relapse after R1 surgery was controlled
by chemoradiation for long term in the current case.
Since survival rate of R1 surgery is worse than R0
surgery in ECC [4], patients with borderline resect-
able ECC, who are potentially candidates for R1 sur-
gery, need optimal multimodal treatment in addition
to the planned surgery.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompanying
images.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HO described and designed the article. AC and DH edited the article. HB and
YM supervised the edition of the manuscript. Other remaining co-authors
collected the data and discussed the content of the manuscript. All authors
read and approved the final manuscript.
Author details
1Department of Gastroenterological Surgery, Graduate School of Life
Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Kumamoto
860-8556, Japan. 2Department of Multidisciplinary Treatment for
Gastroenterological Cancer, Kumamoto University Hospital, 1-1-1 Honjo,
Kumamoto, Kumamoto 860-8556, Japan. 3Department of Surgery and
Science, Graduate School of Medical Sciences, Kyushu University, 1-1-1
Honjo, Kumamoto, Kumamoto 860-8556, Japan.
Received: 8 January 2016 Accepted: 22 June 2016
References
1. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al.
Liver transplantation with neoadjuvant chemoradiation is more effective
than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451–8.
discussion 8–61.
2. Patel T. Cholangiocarcinoma—controversies and challenges. Nat Rev
Gastroenterol Hepatol. 2011;8:189–200. doi:10.1038/nrgastro.2011.20.
3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et
al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
New Engl J Med. 2010;362:1273–81. doi:10.1056/NEJMoa0908721.
4. Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, et al. Clinicopathologic
study of cholangiocarcinoma with superficial spread. Ann Surg. 2009;
249:296–302. doi:10.1097/SLA.0b013e318190a647.
5. Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The
pattern of infiltration at the proximal border of hilar bile duct carcinoma: a
histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–11.
6. Im JH, Seong J, Lee IJ, Park JS, Yoon DS, Kim KS et al. Surgery alone versus
surgery followed by chemotherapy and radiotherapy in resected
extrahepatic bile duct cancer: treatment outcome analysis of 336 patients.
Cancer Res Treat: official journal of Korean Cancer Association. 2015.
doi:10.4143/crt.2015.091.
7. Moureau-Zabotto L, Turrini O, Resbeut M, Raoul JL, Giovannini M, Poizat F, et al.
Impact of radiotherapy in the management of locally advanced extrahepatic
cholangiocarcinoma. BMC cancer. 2013;13:568. doi:10.1186/1471-2407-13-568.
8. Habermehl D, Lindel K, Rieken S, Haase K, Goeppert B, Buchler MW, et al.
Chemoradiation in patients with unresectable extrahepatic and hilar
cholangiocarcinoma or at high risk for disease recurrence after resection:
analysis of treatment efficacy and failure in patients receiving postoperative
or primary chemoradiation. Strahlenth Onkol: Organ der Deutschen
Rontgengesellschaft. 2012;188:795–801. doi:10.1007/s00066-012-0099-y.
Table 1 Outcome of concomitant treatment plus R1 surgery in patients with ECC





2006 81 Surgery + RT (45–59 Gy) + CTx (5FUa or GEM) R0:12, R1:16 11 (39.3) – 7 (25.0) – 9
2012 25 Surgery + RT (45–50Gy) + CTx (GEM) 8 1 (12.5) – 4 (50.0) – 8
2013 25 Surgery→ local relapse→ EBRT (48Gy) + CTx
(CDDP or 5FUa)
6 2 (33.3) – 3 (50.0) – 7
2015 336 Surgery alone 22 13 (59.1) 0.003 16 (72.7) 0.007 6
Surgery + CTx (5FUa + CDDP or GEM) 12 7 (58.3) 3 (25.0)
Surgery + RT (40–50 Gy) 13 2 (15.4) 6 (46.2)
Surgery + CRT (5FUa or GEM + RT) 20 3 (15.0) 5 (25.0)
RT radiation, CTx chemotherapy, GEM gemzal, EBRT external beam radiation therapy, CDDP cisplatin, CRT chemoradiation
a5FU: 5-Fluorouracil-based chemotherapy such as capecitabine, TS1, and infusion of 5FU
Okabe et al. Surgical Case Reports  (2016) 2:69 Page 5 of 6
9. Ben-David MA, Griffith KA, Abu-Isa E, Lawrence TS, Knol J, Zalupski M, et al.
External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int
J Radiat Oncol Biol Physics. 2006;66:772–9. doi:10.1016/j.ijrobp.2006.05.061.
10. Fuller CD, Wang SJ, Choi M, Czito BG, Cornell J, Welzel TM, et al. Multimodality
therapy for locoregional extrahepatic cholangiocarcinoma: a population-based
analysis. Cancer. 2009;115:5175–83. doi:10.1002/cncr.24572.
11. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and
oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a
multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:
181–8. doi:10.1016/S1470-2045(11)70301-1.
12. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al.
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-
tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Lancet Oncol. 2014;15:819–28. doi:10.1016/S1470-2045(14)70212-8.
13. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose
adjustment of 5-fluorouracil: a rational approach to improving therapeutic
outcomes. J Natl Cancer Inst. 2009;101:1543–52. doi:10.1093/jnci/djp328.
14. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al.
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for
perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):
88–98. e3; quiz e14. doi:10.1053/j.gastro.2012.04.008.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Okabe et al. Surgical Case Reports  (2016) 2:69 Page 6 of 6
